Class: Gallstone solubilizing agent
- Capsules 300 mg
- Tablets 250 mg
- Tablets 500 mg
URSO DS (Canada)
Suppresses hepatic synthesis and cholesterol secretion and inhibits intestinal absorption of cholesterol.
About 90% absorbed in the small bowel.
Extracted from portal blood in the liver where it is conjugated with glycine or taurine and then secreted into the hepatic bile ducts. These conjugates are absorbed in the small intestine. The conjugates is deconjugated in the ileum, leading to formation of free ursodiol that can be reabsorbed and reconjugated in the liver. Some ursodiol is epimerized to chenodiol, which may undergo 7-hydroxylation to lithocholic acid.
Various metabolites (including chenodiol, lithocholic acid, and sulfated lithocholic acid conjugates) are excreted in the feces.
Indications and Usage
Dissolution of gallstones in patients with radiolucent, noncalcified, gallbladder stones less than 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for patients refusing surgery (capsules only); prevention of gallstone formation in obese patients experiencing rapid weight loss (capsules only); treatment of patients with primary biliary cirrhosis (tablets only).
Cholestasis-associated pruritus; primary sclerosing cholangitis.
Hypersensitivity to any component of product.Capsule only
Presence of calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones; patients with compelling reasons for cholecystectomy, including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-GI fistula; allergy to bile acids.
Dosage and AdministrationGallstone Dissolution
PO 8 to 10 mg/kg/day in 2 or 3 divided doses.Gallstone Prevention
PO 300 mg twice daily.Primary Biliary Cirrhosis
PO 13 to 15 mg/kg/day in 2 to 4 divided doses with food.
Store tablets at controlled room temperature (68° to 77°F). Store capsules at controlled room temperature (59° to 86°F).
Drug InteractionsAntacids, bile acid sequestrants
May decrease ursodiol absorption.Clofibrate, estrogens, oral contraceptives
May decrease the efficacy of ursodiol by increasing hepatic cholesterol secretion and encouraging cholesterol gallstone formation.
Laboratory Test Interactions
None well documented.
The following adverse reactions occurred at an incidence rate of 5% or more.
Asthenia; dizziness; fatigue; headache; insomnia.
Abdominal pain; cholecystitis; constipation; diarrhea; dyspepsia; flatulence; GI disorder; nausea; vomiting.
Arthralgia; arthritis; back pain; musculoskeletal pain; myalgia.
Bronchitis; coughing; sinusitis; upper respiratory tract infection.
Allergy; chest pain; influenza-like symptoms; peripheral edema; viral infection.
Category B .
Safety and efficacy not established.
Studies suggest bile acids might be involved in pathogenesis of human colon cancer in patients undergoing a cholecystectomy; however, direct evidence is lacking.
Gallbladder nonvisualization developing during treatment predicts failure of complete stone dissolution and treatment should be discontinued.
May recur within 2 yr in 30% of patients and within 5 yr in 50% of patients.
The lithocholic acid metabolite of ursodiol is hepatotoxic; therefore, monitor AST and ALT.
- Emphasize to patient that effective treatment will require months of treatment.
- Advise patient to read patient information leaflet before starting therapy and with each refill.
- Advise patient taking tablets to take 2 to 4 times daily with food as prescribed. Advise patient to swallow tablets whole and not to chew, crush, or break because contents of tablet have a bitter taste.
- Advise patient taking capsules to take 2 or 3 times daily as prescribed. Advise patient to take without regard to meals but to take with food if stomach upset occurs. Advise patient to swallow capsules whole and not to chew, crush, or open because contents of capsule have a very bitter taste.
- Advise patient that if a dose is missed to skip that dose and take the next dose at the regularly scheduled time.
- Caution patient not to change the dose or stop taking unless advised by health care provider.
Copyright © 2009 Wolters Kluwer Health.
More Ursodiol resources
- Ursodiol Monograph (AHFS DI)
- Ursodiol Prescribing Information (FDA)
- ursodiol MedFacts Consumer Leaflet (Wolters Kluwer)
- ursodiol Concise Consumer Information (Cerner Multum)
- ursodiol Advanced Consumer (Micromedex) - Includes Dosage Information
- Actigall Prescribing Information (FDA)
- Urso Prescribing Information (FDA)